CHMP recommends Rebif use in patients with early signs of MS
This article was originally published in Scrip
Experts on the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) are recommending that the terms of the European market authorisation of Rebif (interferon beta-1a) should be amended to treat patients with early signs of multiple sclerosis. The CHMP is recommending that 44 micrograms of Rebif three times weekly should be given to patients who have experienced a single demyelinating event, an early sign of multiple sclerosis, and who are at high risk of developing the disease.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.